Market Overview
[180 Pages Report] The Pectus bar system Market is estimated to reach at a Significant CAGR during the forecast period (2024-2031).
The Pectus Support Bar helps the surgeon for treating the pectus excavatum, funnel chest, a congenital deformity that is often accompanied by breath shortness in children. The device is not intended to replace chest wall structures.
Market Scope
| Metrics | Details |
| Market CAGR | Prominent Growth |
| Segments Covered | By Product Type, By Material Type, By End-User nd By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights Download Sample
Market Dynamics
The efficiency of the Nuss procedure will drive the market, and the increasing research and development activities to develop a highly compatible pectus bar will drive the market in the forecast period.
The efficiency of the Nuss procedure will drive the pectus bar system market
The Nuss procedure is the preferred operation for surgical correction of pectus excavatum (PE). It is a minimally invasive technique whereby one to three curved metal bars are inserted behind the sternum to push into a normal position. These bars are left in situ for three years and then removed. Due to the popularity of the Nuss procedure and the accumulation of surgical experience, especially in adult patients, the increased use of more than one bar for correction of the sunken chest wall has also been reported recently. In Nuss surgery, the number of bars used is determined primarily by the gross appearance of the deformity. But in the case of women (because of the breasts) and obese patients, the deformation of the bone cage is not completely even with the external deformity of the chest wall.
According to published data evaluating the success rate of the Nuss procedure indicates that recurrence is reported in less than 2% of cases. In the Nuss Procedure, there is a significant benefit of the high probability of successful deformity correction and a low chance of recurrence.
Increased research and development activities to develop a highly compatible pectus bar will drive the market in the forecast period
Pectus Excavatum (PE) represents a depression in the anterior chest wall resulting from a dorsal deviation of the sternum. PE is the most frequent chest deformity in children, affecting 0.4%–1% of the population, with a 4:1 ratio of male to female. Deformities of the chest wall are characterized by a funnel-shaped anterior region and by the reduction of the distance between the sternum and the spinal column. The double-bar correction appears to be effective for treating pectus excavatum. The cross-bar insertion technique might be superior to the parallel bar insertion technique for correcting a wider range of deformities, especially at the lower part of the depression.
Reconstructive repair of chest wall deformities may involve metal bars, struts, and stabilizers to correct the defect. These appliances are categorized as Class II medical devices by the U.S. Food and Drug. Administration (FDA) and numerous manufacturers have received 510(k) FDA approval for bone fixation devices to repair PE and other anterior chest wall deformities. Examples include Park's Pectus System (TDM Co. Ltd., Houston, TX) and the Lorenz Pectus Support Bar System (W. Lorenz Surgical, Inc., Jacksonville, FL).
Side effects related to the pectus bar system will hamper the market
Severe pectus excavatum can compress the heart and lungs or even may push the heart over to one side. Pectus excavatum can result in self-image problems in some mild cases. If the depth of the breastbone indentation is severe it will reduce the amount of room for the lungs to expand. This compression squeezes the heart, pushing it into the left side of the chest and reducing its ability to pump efficiently. This causes symptoms such as exercise intolerance, shortness of breath, rapid heart rate and chest pain. Many people who have pectus excavatum tend to have a hunched-forward posture, shoulder blades and flared ribs. Due to self-consciousness about their appearance, many people avoid activities, such as swimming, that make the indentation in their chests more difficult to camouflage behind clothing.
After Nuss repair pectus bar removal is associated with major complications that are not reported. One of the main concerns is surgical bleeding. Old age and placement of more than one bar are reported risk factors for pectus bar removal. This study presented our experience regarding the modified skills required to minimize complications during bar removal, especially in adult patients.
COVID-19 Impact Analysis On Market
The COVID-19 has impacted pectus excavatum surgeries which have affected the Pectus bar system Market The healthcare system has turned to combat COVID-19. This has gradually declined the surgeries involving the use of the pectus bar system and will affect its demand.
Market Segment Analysis
The implant segment will dominate the pectus bar system market
A surgical technique used to treat most pectus excavatum involves placing an implant under the skin, soft tissue, and muscle layer in front of the breast bone to mask the deformity. Compared to other types of surgery that correct the deformity, it is a minor, less invasive surgical procedure.
Previously, such implants were variable depending on patient selection, the technique used, and an implant inserted. More recently, custom-made implants based on 3D reconstructive technologies have been developed, which significantly improve the cosmetic result—3D customized implants procedure. Pectus excavatum repair using Anatomik Modeling implants lasts about 45 minutes.
Stainless steel has dominated the market
Stainless steel has adequate strength, flexibility, ductility, and bio-compatibility for most maxillofacial implant applications. In addition, it is relatively cheap and easy to manufacture. Stainless steel alloys are used for orthopedic and implant devices.
Stainless steel bars were used initially in the Nuss procedure for pectus excavatum. Stainless steel contains various metals, such as iron-chromium, nickel, molybdenum, which are not antigens themselves. To avoid recurrent depression of sternum after repair of pectus excavatum, currently, most surgeons do some postoperative sternal fixation. External sternal support was not used for a few decades however, a variety of techniques for internal stabilization have been recommended, including a substernal autologous rib strut, Kirschner wires, or Steinmann pins placed behind the lower sternum and attached laterally to the ribs. Thin stainless steel struts have increased frequency during the past several years as temporary supports in adolescents and children with tall body configurations. For young children, autologous perichondrium placed behind the sternum is a simple technique to provide support without a prosthesis. Haller and associates avoided prosthetic or autologous sternal support in favor of modifying Ravitch's technique of internal suspension, with overlapping of the bevelled ends of the lowest normal costal cartilages bilaterally.
The hospital segment will dominate the market
An increase in the number of pectus excavatum surgeries, the number of skilled healthcare workers, and the proper availability of instruments in hospitals will drive the market. Length of stay in the hospital is determined primarily by pain control as the surgical repair of pectus excavatum is a painful procedure. The recovery after pectus excavatum repair varies as with any surgical procedure. After surgery, most of the patients are in the hospital for about 4-5 days and when the pain is controlled on medications and they feel well, they can be discharged home. Follow-up appointments in the thoracic surgery clinic are scheduled 1-2 weeks after discharge with a chest X-ray. Hence, the hospital segment will dominate the Pectus bar system Market
Market Geographical Share
North America region will dominate the pectus bar system
Due to new product innovations, high adoption of minimally invasive surgeries, and growing awareness of new products will dominate the market in this region.
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, has received U.S. FDA 510(k) clearance of additional labelling claims for cryo nerve block (cryoNB) therapy which can include the treatment of adolescent patients (12-21 years of age). After undergoing invasive surgery, adolescent patients chest walls can experience severe pain and have limited options for pain management. The preferred corrective procedure for structural deformities of the chest wall is a minimally invasive surgery known as the Nuss procedure, and cryoNB therapy has shown to be safe and effective for postoperative pain management for adolescent patients.
In the U.S in 2018, American Society of Plastic Surgeons (ASPS) members reported that more than 17.7 million surgical and minimally invasive aesthetic procedures were performed. That's nearly 277,000 more cosmetic procedures than in the previous year.
Market Companies
Major key players in the pectus bar system market are Reid Healthcare, IDEAR S.R.L., Inc., Biotech GmbH., Zimmer Biomet, Ventura Medical Technologies, MedXpert GmbH, Surgical Specialties Corporation, Shanghai Sun-Shore Medical Instruments Co., Ltd., Qingdao Sinoland Medical Technology Co., Ltd. and Anhui Intrag Medical Techs Co., Ltd.
Pectus bar system Market Key Companies to Watch
Zimmer Biomet
Overview: Zimmer Biomet has been based in Warsaw since it was founded in 1927. This company has their services in more than 25 countries worldwide and sells products in more than 100 countries. Musculoskeletal technologies, a wide range of related products and services make them partners to healthcare providers in more than 100 countries. They are building on a strong history of success to enhance the value that provides to healthcare providers and their patients. They maintain world-class scientific facilities and resources and collaborate with leading clinicians, researchers around the world. They share a commitment with healthcare providers to find the best technologies, treatments, and solutions to deliver high-quality, cost-effective patient care.
Product Portfolio: The company designs, manufactures and markets effective, innovative solutions which help orthopedic surgeons and clinicians in alleviating pain and improving the quality of life for people worldwide.
Key Developments:
On Jan. 25, 2019, Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced U.S. Food and Drug Administration 510(k) clearance of the ROSA® Knee System for robotically-assisted total knee replacement surgeries. ROSA Knee features 3D pre-operative planning tools and real-time, intraoperative data on soft-tissue and bone anatomy designed to improve bone cut accuracy and range of motion gap analysis to improve flexion and restoration of natural joint movement potentially.
